Searchable abstracts of presentations at key conferences in endocrinology
Endocrine Abstracts (2023) 90 P367 | DOI: 10.1530/endoabs.90.P367

ECE2023 Poster Presentations Diabetes, Obesity, Metabolism and Nutrition (159 abstracts)

Diabetic keto-acidosis secondary to sodium glucose co-transporter inhibitors: single-centre experience

Mikhail Nozdrin 1 , Maria Selyanina 2 , suhier elshowaya 1 , Ghada Ahmed 1 , Blazej Rzeszowski 3 , Rafael Abreu 4 , Simona Mihalikova 2 & Gideon Mlawa 1


1Queen’s Hospital, United Kingdom; 2St Bartholomew’s Hospital, United Kingdom; 3Imperial College London, London, United Kingdom; 4Hialeah Hospital, Hialeah, United States


Background: SGLT-2 inhibitors (SGLT-2i) are used in treatment of type 2 diabetes mellitus (T2DM) through increasing urinary glucose secretion. Cases of euglycemic and hyperglycaemic diabetic ketoacidosis (DKA) have been reported in literature in patients using SGLT-2i. Increased glucose urinary excretion promoted by SGLT2i, decreases the production of insulin. In turn, lipolysis and ketone production increase predisposing the patient to developing DKA. It is hypothesised that SGLT2i, stimulate a cells of the pancreas, increasing the release of glucagon. The increased glucagon levels, further stimulate B-oxidation and ketone body production. In our case series we aim to describe the risk factors, demographics associated with development of SGLT-2i associated DKA and the course of disease in such patients.

Methods: All the T2DM patients with diabetic ketoacidosis on SGLT-2i who presented to the emergency department of a large hospital between Dec 26th 2018 and Jan 1st 2023 were included in the study.

Table 1 Comparison of CGM metrics before and after AID initiation, nZ185
Before AID InitiationAfter AID InitiationP value
CGM wear time,% 81.25G16.9 88.44G12.71 <0.001
CGM data, days 76.39G18.8 81.11G16.47 0.002
Mean sensor glucose, mg/dl 167.57G29.23 150.32G18.36 <0.001
Glucose management indicator(GMI),% 7.3G0.7 6.90G0.44 <0.001
SD 59.40G13.17 49.16G10.12 <0.001
CV,% 35G5 33G4 <0.001
Time below range, <70 mg/dl(TBR),% 3.23G3.33 1.97G1.98 <0.001
Time between 54-70 mg/dl(TBR2),% 0.65G1.03 0.36G0.5 <0.001
Time below 54 mg/dl(TBR1),% 2.58G2.39 1.62G1.52 <0.001
Time in range, 70-180 mg/dl(TIR),% 58.95G17.29 73.56G11.66 <0.001
Time above range, >180 mg/dl(TAR),% 37.81G18.29 24.47G12.18 <0.001
Time between 181-250 mg/dl,(TAR1),% 24.99G8.92 18.87G7.75 <0.001
Time above 250 mg/dl(TAR2),% 12.83G11.26 5.60G5.15 <0.001
GRI 48.66G21.81 29.01G13.01 <0.001
GRI-Hypoglycemia component 2.72G2.85 1.65G1.68 <0.001
GRI-Hyperglycemia component 25.32G14.52 15.03G8.52 <0.001

Results: Ten patients were included in the study. Patient demographics are summarised in Table 1. All patients had confirmed T2DM, with negative GAD and anti-islet antibodies. Five patients were taking Canagliflozin, four-Empagliflozin, one-Dapagliflozin. Mean blood ketone level on admission was 4.18 mmol/l (2 St.Dev. ±0.274) and venous blood gas pH was 7.088 (2 St. Dev. ±0.155). Blood glucose on admission ranged from (4.7 to 28 mmol/l). Most common symptom at presentation was vomiting (n=5). Other common symptoms at presentation were abdominal pain (n=2), shortness of breath (n=2) and lethargy (n=2). Four patients had concurrent illness at presentation: urosepsis, recent knee surgery, community acquired pneumonia and acute coronary syndrome. All patients were treated with sliding scale, 1 patient was transferred to ITU, 1 required HDU support and 1 passed away from a cardiac arrest in ED. Mean duration of hospital stay was 5.3 days (2 St. Dev: 2.46 days).

Discussion: Diabetic ketoacidosis secondary to SGLT2i is a known side effect. In our cohort, we found 3 patients presenting with hyperglycaemia. DKA with SGLT2i is not uncommon, especially with intercurrent illness. Therefore patients on this therapy should be encouraged to monitor their blood ketone levels even if their blood glucose levels are within range.

Volume 90

25th European Congress of Endocrinology

Istanbul, Turkey
13 May 2023 - 16 May 2023

European Society of Endocrinology 

Browse other volumes

Article tools

My recent searches

No recent searches.